| abstract |
The object of the present invention is a compound corresponding to the following formula (I): In the formula, —R 1 represents a hydrogen atom or a (C 1 -C 4 ) alkyl group; —R 2 represents homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl, or azetidine-1 - represents yl radical or an amino (C 1 -C 6) alkyl group; or, R 1 and R 2, together with the nitrogen atom to which they are attached, piperazin-1-yl, 1,4-diazepane Comprises a -1-yl radical, homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical; one of the two substituents R 3 , R 6 is Y It represents -A-R 9 group; -Y is an oxygen atom or -S (O) n, -, OSO 2 -, or -N (R 18) - represents a group; -A is unsubstituted (C 1 -C 4) alkylene group; -R 9 is -OR 12, -CN, -CO 2 H , NR 12 R 13, -CONR 12 R 13, -NR 15 COR 12, -CONHNH 2, -CONHOH, -CONHSO 2 R 14, -S (O) n R 14 , —SO 2 NR 12 R 13 , —NR 18 SO 2 R 14 , or —NR 15 SO 2 NR 12 R 13 group, or an aromatic heterocyclic ring. The present invention also relates to a process for the preparation of compounds of formula (I) and therapeutic use as cannabinoid CB1 receptor antagonists. |